Background: In Equatorial Guinea, malaria continues to be one of the main causes of morbidity and mortality among children. The National Therapeutic Guide established artesunate-amodiaquine (ASAQ) as first-line treatment for uncomplicated malaria, but compliance with this treatment is low. The aim of this study was to assess, for the first time, the performance of public healthcare workers in the diagnosis and treatment of uncomplicated malaria, their compliance with first-line Malaria National Therapeutic Guide and the associated factors.
Methods: A cross-sectional survey was conducted at the nine public health facilities in the Bata District of Equatorial Guinea to assess the management of uncomplicated malaria in children < 15 years of age. Bivariate and multivariate statistical analyses were used to determine the recommended treatment compliance and related factors.
Results: A total of 227 children with uncomplicated malaria were recorded from 9 public health facilities. Most of the treatments prescribed (83.3%) did not follow the first-line treatment recommended for uncomplicated malaria. The diagnosis was established with parasite confirmation in 182 cases (80.2%). After adjustment for other variables, children under 2 months of age, the use of parasite confirmation to the diagnosis of malaria and being familiar with the national therapeutic guide were significantly associated with the prescription of the first-line recommended treatment. Cases attended at the hospital or in a health facility with ASAQ in the pharmacy at the time of the study were also more likely to be prescribed with the recommended treatment, but with non-significant association after adjustment for other variables.
Conclusions: This study identified the factors associated with the low compliance with the first-line treatment by the public healthcare facilities of Bata District of Equatorial Guinea. It seems necessary to improve case management of children with uncomplicated malaria; to reinforce the use of Malaria National Therapeutic Guide and to inform about the danger of using artemisinin monotherapy. Furthermore, it is crucial to provide recommended first-line treatment to the pharmacies of all public health facilities to ensure access to this treatment.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6677319 | PMC |
http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0220789 | PLOS |
Sudan J Paediatr
January 2024
Independent Consultant, Lawrenceville, Georgia, USA.
This is a brief review that highlights recent updates in malaria case management. Recent WHO revisions include a new artemisinin-based molecule (artesunate-pyronaridine), revising the recommendations for treating uncomplicated malaria during the first trimester of pregnancy and optimising primaquine dose to prevent relapses. The review also highlights innovative ideas to improve the implementation of guidelines for severe malaria and pre-referral treatment with rectal artesunate.
View Article and Find Full Text PDFActa Med Indones
October 2024
Division of Tropical and Infectious Diseases, Department of Internal Medicine, Faculty of Medicine Universitas Indonesia - Cipto Mangunkusumo Hospital, Jakarta, Indonesia.
In 2023, Indonesia's Ministry of Health reported that nearly 75% of districts and cities in the country were free from malaria transmission, meaning 90% of the population lived in malaria-free zones. However, Papua Province, which accounts for only 1.5% of Indonesia's population, continues to contribute over 90% of the national malaria cases, with more than 16,000 reported cases in 2023.
View Article and Find Full Text PDFActa Med Indones
October 2024
Department of Internal Medicine, Faculty of Medicine Universitas Indonesia - Cipto Mangunkusumo Hospital, Jakarta, Indonesia.
Background: Malaria infection has caused a significant morbidity and mortality, notably in high-risk groups. Some evidence showed that ABO blood types might associate with malaria severity. This study aimed to determine the relationship between blood types and malaria severity in Papua, as Papua is a malaria-endemic area.
View Article and Find Full Text PDFEur J Med Chem
January 2025
Department of Immunology, College of Basic Medical Sciences, China Medical University, Shenyang, 110122, China. Electronic address:
Artesunate, a semisynthetic derivative of artemisinin, is not only recommended as the first-line drug for treating severe malaria but is also a significant member of Artemisinin-based Combination Therapies (ACTs), used in combination with other artemisinin derivatives for treating uncomplicated malaria. Beyond its potent anti-malarial activity, artesunate has garnered considerable attention for its pharmacological effects, which encompass broad-spectrum anti-tumor, anti-viral, and anti-inflammatory properties. It has collectively demonstrated superior drug tolerance, low toxicity, and mild side effects in cell line experiments in vitro, experimental animal models, and clinical drug researches, as a monotherapy or in combination with other agents.
View Article and Find Full Text PDFBiochem Genet
January 2025
Key Laboratory of Parasite and Vector Biology of the Chinese Ministry of Health, Chinese Center for Disease Control and Prevention, WHO Collaborating Centre for Tropical Diseases, National Institute of Parasitic Diseases, Shanghai, 200025, People's Republic of China.
Drug resistance resulting from mutations in Plasmodium falciparum, that caused the failure of previously effective malaria drugs, has continued to threaten the global malaria elimination goal. This study describes the profiles of P. falciparum chloroquine resistance transporter (Pfcrt) and P.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!